适应证：用于治疗猫跳蚤（猫栉首蚤）和蜱（血红扇头蜱、铃头血蜱）感染。本品可作为跳蚤过敏性皮 炎（FAD）临床治疗方案的一部分进行使用。 格隆汇10月13日丨普莱柯(603566.SH)公布，根据《兽药管理条例》和《兽药注册办法》规定，经农业 农村部审查，批准公司及其全资子公司洛阳惠中兽药有限公司（以下简称"惠中兽药"）等单位联合申报 的"氟雷拉纳滴剂"为新兽药，并于2025年10月11日公示了核发《新兽药注册证书》（中华人民共和国农 业农村部公告第957号）事项。 ...

Core Viewpoint - The approval of "Fluralaner Drops" as a new veterinary drug by the Ministry of Agriculture and Rural Affairs marks a significant development for the company and its wholly-owned subsidiary, Luoyang Huizhong Veterinary Medicine Co., Ltd, as it addresses a gap in the market for flea and tick treatment in cats [1] Company Summary - The company, 普莱柯 (603566), has received official approval for its new veterinary drug, "Fluralaner Drops," which is intended for the treatment of flea and tick infections in cats [1] - The drug has been registered and the registration certificate was publicly announced on October 11 [1] Industry Summary - As of now, there are no similar products available in the market, indicating a potential competitive advantage for the company in the veterinary pharmaceutical sector [1]